SAN DIEGO -- Treatment with hydroxyurea led to more hematologic dose-limiting toxicities (DLTs) compared with placebo in patients with hemoglobin SC, a milder form of sickle cell disease (SCD), a ...

Hydroxyurea is an antineoplastic agent, prescribed for sickle cell anemia, several types of cancer (such as melanoma, chronic myelogenous leukemia, squamous cell carcinomas), as an adjunct to ...